GH Research (GHRS) presents clinical data at ECNP 2025

GH Research PLC filed a Form 6-K announcing the presentation of data from its GH001-TRD-201 clinical trial at the 38th European College of Neuropsychopharmacology annual meeting in Amsterdam.

Accepted by SEC EDGAR 10/14/2025 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

GH Research PLC filed a Form 6-K announcing the presentation of data from its GH001-TRD-201 clinical trial at the 38th European College of Neuropsychopharmacology annual meeting in Amsterdam. The Congress is scheduled for October 11–14, 2025.

The presentation, delivered by Prof. Wiesław J. Cubała on October 13, 2025 during the Novel Therapies Symposium, is provided as Exhibit 99.1. This update is informational and centers on the public disclosure of clinical data via a scientific conference presentation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GHRS announce in this Form 6-K?

The company announced a presentation of data from its GH001-TRD-201 clinical trial at the 38th ECNP annual meeting.

When and where is the ECNP Congress taking place?

The Congress is scheduled for October 11–14, 2025 in Amsterdam, the Netherlands.

Who presented the GH001-TRD-201 data for GHRS?

Prof. Wiesław J. Cubała, MD, PhD, delivered the presentation on October 13, 2025.

What exhibit contains the presentation materials for GHRS?

The presentation is attached as Exhibit 99.1.

What is the filing type for this GHRS update?

It is a Form 6-K report of a foreign private issuer.

Does the 6-K include financial results for GHRS?

No. It provides notice and materials related to a scientific conference presentation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

GH Research PLC announces the presentation of data from its GH001-TRD-201 clinical trial at the 38^th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands (the “Congress”).

A copy of the presentation delivered by Prof. Wiesław J. Cubała, MD, PhD, on October 13, 2025, as part of the Novel Therapies Symposium during the Congress, is attached hereto as Exhibit 99.1.

1

EXHIBIT INDEX

99.1 Presentation by Prof. Wiesław J. Cubała with Title: Long-Term Data for GH001 in Patients with Treatment-Resistant Depression

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: October 14, 2025
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

3